Biotech entity
Donald Trump is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. Across a 175-day span, the pace is roughly 0.2 stories per week.
Last mentioned: 1d ago
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Donald Trump is the most frequent co-covered peer, appearing in 2 of the 4 tracked stories. The clearest coverage concentration is pharma: 3 of 4 stories, with the rest divided among 1 other category. Across a 175-day span, the pace is roughly 0.2 stories per week. Each story carries 2.8 original sources on average, compared with 3.4 for the broader beat in this window. The 5.3 average consequence score is below the beat benchmark of 6.1 in the same window. We currently track 4 Biotech stories that mention Department of Health and Human Services, published between March 19, 2026 and September 9, 2026.
Computed from the 4 stories linked to this entity, with beat comparisons drawn from all 448 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Department of Health and Human Services. Shared-story counts are live from our verified record — not editorial picks.
HHS fills four senior FDA roles
The Department of Health and Human Services announced permanent directors for the FDA's drug, vaccine and biologics, and tobacco centers, along with a fourth senior position.
Hoeg departs CDER
Dr. Tracy Beth Hoeg said she was fired from the Center for Drug Evaluation and Research; Davis began serving in an acting role.
Davis returns to FDA
Michael Davis rejoined the agency as a deputy director after working at a nonprofit pursuing psychedelic drug development.
A former psychiatric drug regulator with psychedelic nonprofit experience now leads FDA's drug center as Trump and RFK push faster reviews. Biopharma teams should watch psilocybin, MDMA and LSD programs plus the new vaccines center director.
Source: whec.com · orlandosentinel.com
Senator Bill Cassidy's public denouncement of HHS Secretary Kennedy for building health policy on lies injects fresh uncertainty into the biotech and pharma industry. Vaccine research and markets face headwinds if top federal officials continue to sow distrust, potentially altering investment and development pipelines.
Source: cbsnews.com · yahoo.com
The Pentagon’s new mandate to screen all troops 30+ for low testosterone could inject millions of potential new patients into the testosterone replacement therapy market, but biotech investors face a dilemma: the policy lacks clinical evidence, urologists are skeptical, and an FDA or congressional backlash could stall the windfall.
The Trump administration has launched a federal investigation into states that mandate abortion coverage in private health insurance plans. This move leverages federal conscience protection laws to challenge state-level healthcare regulations, potentially jeopardizing billions in federal funding.
Department of Health and Human Services is linked from 4 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
